Posts tagged annual revenue
IntelGenx in licensing pact with Chemo Group

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has entered into a licensing, development and supply agreement with closely-held Chemo Group, granting Chemo the exclusive license to commercialize two generic products for the U.S. market and one product on a worldwide basis.

The Chemo Group is a global pharmaceutical company with over 5,000 employees, operations in over 40 countries and annual revenue of more than $1.2-billion.

Read More